Meeting
2023 ASCO Genitourinary Cancers Symposium
A real-world registry of patients with metastatic castration-resistant prostate cancer (mCRPC): REMPRO study.
Authors
Francisco Gonzalez
AstraZeneca UK LTD, Macclesfield, United Kingdom
Francisco Gonzalez , Rohit Kodagali , Teresa Tung , Mohamed Masoud , Viraj Rajadhyaksha
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04801186
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS286)
DOI
10.1200/JCO.2023.41.6_suppl.TPS286
Abstract #
TPS286
Poster Bd #
Q8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) and tumors harboring androgen receptor (AR) ligand-binding domain (LBD) mutations.
First Author: Tyler F. Stewart
Poster
2023 ASCO Genitourinary Cancers Symposium
The impact of homologous recombination repair (HRR) gene mutation status on treatment (tx) patterns and clinical outcomes among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US).
First Author: Pedro C. Barata
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns and progression-free survival among patients with metastatic castration-resistant prostate cancer: Examining the benefits of sequential androgen receptor pathway inhibitor use.
First Author: Jeetvan Patel
Poster
2023 ASCO Genitourinary Cancers Symposium
Survival outcomes of metastatic castration-resistant prostate cancer in Brazil (LACOG 1818).
First Author: Fernando Cotait Maluf